8th ASM Biodefense & Emerging Diseases Conference

For the third time in less than 2 years Pherecydes Pharma is presenting at a biofense conferences, in the USA.

Hôpital Robert Debré collaboration

On February 7th, 2010, Robert Debré Hospital (Paris-France) and Pherecydes Pharma signed an agreement to select bacteriophage variants for eradicating different Escherichia coli strains.

Read all news

TAPE R&D collaboration

TAPE: Targeted Accelerated Protein Evolution

TAPE is the building block:

Of a renewal strategy for biodrugs getting off patent;
Of a discovery program to select new leads with better targets kinetics;
Of a molecule optimization process to derive new monoclonal antibody clones with improved epitope affinity.

Starting from a characterized gene, we offer to provide large DNA banks, encoding for analogues of proteins, enzymes or antibodies from a given known target. Variant DNA sequences code for a high diversity analogue collection with preserved conserved domains and mutated variable regions.

The offer can be limited to the development of large variant DNA banks or go all the way to the selection of the best bio analogues tested for efficacy on a given target, in comparison to the genuine molecule.

The offer may include a non-exclusive patent licence of TAPE technology for in house testing.